542 related articles for article (PubMed ID: 32911014)
1. Bioresponsive drug delivery systems for the treatment of inflammatory diseases.
Dou Y; Li C; Li L; Guo J; Zhang J
J Control Release; 2020 Nov; 327():641-666. PubMed ID: 32911014
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases.
Deng Z; Liu S
Drug Deliv Transl Res; 2021 Aug; 11(4):1475-1497. PubMed ID: 33860447
[TBL] [Abstract][Full Text] [Related]
3. Smart Responsive Quercetin-Conjugated Glycol Chitosan Prodrug Micelles for Treatment of Inflammatory Bowel Diseases.
Shen C; Zhao L; Du X; Tian J; Yuan Y; Jia M; He Y; Zeng R; Qiao R; Li C
Mol Pharm; 2021 Mar; 18(3):1419-1430. PubMed ID: 33522827
[TBL] [Abstract][Full Text] [Related]
4. Wielding the double-edged sword: Redox drug delivery systems for inflammatory bowel disease.
Chen Y; Shui M; Yuan Q; Vong CT; Yang Z; Chen Z; Wang S
J Control Release; 2023 Jun; 358():510-540. PubMed ID: 37169178
[TBL] [Abstract][Full Text] [Related]
5. Bioresponsive functional nanogels as an emerging platform for cancer therapy.
Huang D; Qian H; Qiao H; Chen W; Feijen J; Zhong Z
Expert Opin Drug Deliv; 2018 Jul; 15(7):703-716. PubMed ID: 29976103
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting.
Bertoni S; Machness A; Tiboni M; Bártolo R; Santos HA
Biopolymers; 2020 Jan; 111(1):e23336. PubMed ID: 31724750
[TBL] [Abstract][Full Text] [Related]
7. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
[TBL] [Abstract][Full Text] [Related]
8. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
Li S; Xie A; Li H; Zou X; Zhang Q
J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
[TBL] [Abstract][Full Text] [Related]
9. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.
Teruel AH; Gonzalez-Alvarez I; Bermejo M; Merino V; Marcos MD; Sancenon F; Gonzalez-Alvarez M; Martinez-Mañez R
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899548
[TBL] [Abstract][Full Text] [Related]
10. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.
Ulbrich W; Lamprecht A
J R Soc Interface; 2010 Feb; 7 Suppl 1(Suppl 1):S55-66. PubMed ID: 19940000
[TBL] [Abstract][Full Text] [Related]
11. Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease.
Pu Y; Fan X; Zhang Z; Guo Z; Pan Q; Gao W; Luo K; He B
J Control Release; 2023 Feb; 354():1-18. PubMed ID: 36566845
[TBL] [Abstract][Full Text] [Related]
12. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X
Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 inflammation and implications in drug delivery.
Zoulikha M; Huang F; Wu Z; He W
J Control Release; 2022 Jun; 346():260-274. PubMed ID: 35469984
[TBL] [Abstract][Full Text] [Related]
14. Cleavage and Noncleavage Chemistry in Reactive Oxygen Species (ROS)-Responsive Materials for Smart Drug Delivery.
Chi T; Sang T; Wang Y; Ye Z
Bioconjug Chem; 2024 Jan; 35(1):1-21. PubMed ID: 38118277
[TBL] [Abstract][Full Text] [Related]
15. Bioresponsive Injectable Hydrogels for On-demand Drug Release and Tissue Engineering.
Vashist A; Kaushik A; Alexis K; Dev Jayant R; Sagar V; Vashist A; Nair M
Curr Pharm Des; 2017; 23(24):3595-3602. PubMed ID: 28521694
[TBL] [Abstract][Full Text] [Related]
16. Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives.
Kotla NG; Rana S; Sivaraman G; Sunnapu O; Vemula PK; Pandit A; Rochev Y
Adv Drug Deliv Rev; 2019 Jun; 146():248-266. PubMed ID: 29966684
[TBL] [Abstract][Full Text] [Related]
17. Stimulus-Responsive Hydrogels as Drug Delivery Systems for Inflammation Targeted Therapy.
Yu H; Gao R; Liu Y; Fu L; Zhou J; Li L
Adv Sci (Weinh); 2024 Jan; 11(1):e2306152. PubMed ID: 37985923
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
19. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis.
Gou S; Huang Y; Wan Y; Ma Y; Zhou X; Tong X; Huang J; Kang Y; Pan G; Dai F; Xiao B
Biomaterials; 2019 Aug; 212():39-54. PubMed ID: 31103945
[TBL] [Abstract][Full Text] [Related]
20. Advances in bioresponsive closed-loop drug delivery systems.
Yu J; Zhang Y; Yan J; Kahkoska AR; Gu Z
Int J Pharm; 2018 Jun; 544(2):350-357. PubMed ID: 29191483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
